文献速递瓣膜病与结构性心脏病血脂与心血管预防

抑制MFSD5可减少瓣膜病中脂蛋白(a)摄取与钙化

Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease.
PubMed 文献 · Circulation · 2023-11-08

该研究通过配体-受体捕获质谱鉴定MFSD5为脂蛋白(a)摄取的新受体/辅因子。降低MFSD5表达可抑制原代人瓣膜内皮和间质细胞的脂蛋白(a)摄取及钙化;MFSD5变异与主动脉瓣狭窄相关(P=0.027,多重假设检验后),并提示与血浆脂蛋白(a)水平存在交互作用。

要点

  • MFSD5是脂蛋白(a)细胞摄取的新受体/辅因子。
  • 抑制MFSD5可减少人瓣膜细胞脂蛋白(a)摄取与钙化。
  • MFSD5变异与主动脉瓣狭窄相关,支持进一步临床前评估。

核心结论

  • MFSD5敲低抑制人瓣膜细胞脂蛋白(a)摄取和钙化,且MFSD5变异与主动脉瓣狭窄相关,支持进一步临床前评估MFSD5在心血管疾病中的作用。

研究设计与样本

  • 采用无偏配体-受体捕获质谱鉴定MFSD5为脂蛋白(a)摄取的新受体/辅因子。
  • 在原代人瓣膜内皮和间质细胞中,通过计算鉴定的小分子或小干扰RNA降低MFSD5表达。
  • 对MFSD5变异进行meta分析,评估其与主动脉瓣狭窄的关联。

主要发现

  • 降低MFSD5表达可抑制原代人瓣膜内皮和间质细胞的脂蛋白(a)摄取及钙化。
  • MFSD5变异与主动脉瓣狭窄相关(P=0.027,多重假设检验后),并提示与血浆脂蛋白(a)水平存在交互作用。

关键数值与推荐

  • MFSD5变异与主动脉瓣狭窄关联的P=0.027(多重假设检验后)。

临床怎么用

  • MFSD5可能作为减少瓣膜脂蛋白(a)摄取和钙化的潜在干预靶点,需进一步临床前评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aortic valve disease, affecting millions of patients worldwide. Although atherosclerosis is commonly treated with low-density lipoprotein-targeting therapies, these do not reduce Lp(a) or risk of calcific aortic valve disease, which has no available drug therapies. Targeting Lp(a) production and catabolism may provide therapeutic benefit, but little is known about Lp(a) cellular uptake. METHODS: Here, unbiased ligand-receptor capture mass spectrometry was used to identify MFSD5 (major facilitator superfamily domain containing 5) as a novel receptor/cofactor involved in Lp(a) uptake. RESULTS: Reducing MFSD5 expression by a computationally identified small molecule or small interfering RNA suppressed Lp(a) uptake and calcification in primary human valvular endothelial and interstitial cells. MFSD5 variants were associated with aortic stenosis (P=0.027 after multiple hypothesis testing) with evidence suggestive of an interaction with plasma Lp(a) levels. CONCLUSIONS: MFSD5 knockdown suppressing human valvular cell Lp(a) uptake and calcification, along with meta-analysis of MFSD5 variants associating with aortic stenosis, supports further preclinical assessment of MFSD5 in cardiovascular diseases, the leading cause of death worldwide.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rogers MA, Bartoli-Leonard F, Zheng KH, et al. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease. Circulation. 2023. PMID: 37937463. doi:10.1161/CIRCULATIONAHA.123.066822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。